2. Karagianis J., Novick D., Pecenak J., Haro J.M., Dossenbach M., Treuer T., Montgomery W., Walton R., Lowry A.J. Worldwide-Schizophre nia Outpatient Health Outcomes (W-SOHO): Baseline characteristics of panregional observational data from more than 17,000 patients. Int. J. Clin. Pract. 2009; 63(11): 1578–88. DOI: 10.1111/j.1742-1241.2009. 02191.x

3. Любов Е.Б., Любов Е.Б., Ястребов В.С., Шевченко Л.С., Чапурин С.А., Чурилин Ю.Ю., Былим И.А., Гажа А.К., Доронин В.В., Косов А.М., Петухов Ю.Л., Фадеев П.Н. Экономическое бремя шизофрении в России. Социальная и клиническая психиатрия 2012; 22(3): 36–42.

Lyubov E.B., Yastrebov V.S., Shevchenko L.S., Chapurin S.A., Churilin Yu.Yu., Bylim I.A., Gazha A.K., Doronin V.V., Kosov A.M., Petuxov Yu.L., Fadeev P.N.

4. Patel K.R., Cherian J., Gohil K., Atkinson D. Schizophrenia: overview and treatment options. Pharmacy and Therapeutics 2014; 39(9): 638–48.

5. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008; 30(1): 67–76. DOI: 10.1093/epirev/mxn001

6. Bhugra D. The global prevalence of schizophrenia. PLoS medicine 2005; 2(5). DOI: 10.1371/journal.pmed.0020151

7. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC medicine 2004; 2(1): 13. DOI: 10.1186/1741-7015-2-13

8. Yang A.C., Tsai S.J. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int. J. Mol. Sci. 2017; 18(8): 1689. DOI: 10.3390/ ijms18081689

9. Vlatkovic S., Sagud M., Svob Strac D., Sviben M., Zivkovic M., Vilibic M., Vuksan-Cusa B., Mihaljevic-Peles A., Pivac N. Increased prevalence of Toxoplasma gondii seropositivity in patients with treatment-resistant schizophrenia. Schizophr. Res. 2018; 193: 480. DOI: 10.1016/j.schres.2017. 08.006

10. Gutiérrez-Fernández J., de Dios Luna del Castillo J., Mañanes-González S., Carrillo-Ávila J.A., Gutiérrez B., Cervilla J. A., Sorlózano-Puerto A. Different presence of Chlamydia pneumoniae, herpes simplex virus type 1, human herpes virus 6, and Toxoplasma gondii in schizophrenia: meta-analysis and analytical study. Neuropsychiatric Disease and Treatment 2015; 11: 843. DOI: 10.2147/NDT.S79285

11. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 2007; 33(3): 729–36. DOI: 10.1093/schbul/sbl050

12. Mortensen P.B., Nørgaard-Pedersen B., Waltoft B.L., Sørensen T.L., Hougaard D., Torrey E.F., Yolken R.H. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol. Psychiatry 2007; 61(5): 68893. DOI: 10.1016/j.biopsych.2006.05.024

13. Степанова Е.В., Кондрашин А.В., Максимова М.С., Турбабина Н.А., Морозова Л.Ф., Морозов Е.Н., Кинкуль­кина М.А., Лазарева А.В., Бражников А.Ю., Сергиев В.П. Латентный хронический токсоплазмоз и шизофрения. Медицинская паразитология 2019; (1): 18–24. DOI: 10.33092/0025-8326mp 2019.1.18-24.

Stepanova E.V., Kondrashin A.V., Maksimova M.S., Turbabina N.A., Morozova L.F., Morozov E.N., Kinkulina М.A., Lazareva A.V., Brazhnikov A.Yu., Sergiev V.P.

14. Wang T., Wang T., Tang Z.H., Li J.F., Li X.N., Wang X., Zhao Z.J. A potential association between Toxoplasma gondii infection and schizophrenia in mouse models. Exp. Parasitol. 2013; 135(3): 497–502. DOI: 10.1016/j.exppara.2013.08.012

15. Sutterland A.L., Fond G., Kuin A., Koeter M.W.J., Lutter R., van Gool T., Yolken R., Szoke A., Leboyer M., de Haan L. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr. Scand. 2015; 132(3): 161–79. DOI: 10.1111/acps. 12423

16. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophrenia Res. 2003; 62(3): 237–44. DOI: 10.1016/S0920-9964(02)00357-2

17. Webster J.P., Lamberton P.H.L., Donnelly C.A., Torrey E.F. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii’s ability to alter host behaviour. Proceedings of the Royal Society B: Biological Sciences. 2006; 273(1589): 1023–30. DOI: 10.1098/rspb.2005.3413

18. Holub D., Flegr J., Dragomirecká E., Rodriguez M., Preiss M., Novák T., Čermák J., Horáček J., Kodym P., Libiger J., Höschl C., Motlová L.B. Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatrica Scandinavica 2013; 127(3): 227–38. DOI: 10.1111/acps.12031

19. Esshili A., Thabet S., Jemli A., Trifa F., Mechri A., Zaafrane F., Gaha L., Juckel G., Babba H., Jrad B.B. Toxoplasma gondii infection in schizophrenia and associated clinical features. Psychiatry Res. 2016; 245: 327–32. DOI: 10.1016/j.psychres. 2016.08.056

20. Wang H.L., Wang G.H., Li Q.Y., Shu C., Jiang M.S., Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive аnd Toxoplasma-seronegative schizophrenia. Acta Psychiatr. Scand. 2006; 114(1): 40–8. DOI: 10.1111/j.1600-0447.2006.00780.x

21. Fuglewicz A.J., Piotrowski P., Stodolak A. Relationship between toxoplasmosis and schizophrenia: a review. Adv. Clin. Exp. Med. 2017; 26: 1031–6. DOI: 10.17219/acem/61435

22. Stibbs H.H. Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice. Ann. Tropical Med. Parasitol. 1985; 79(2): 153–7. DOI: 10.1080/00034983.1985.11811902

23. McConkey G.A., Martin H.L., Bristow G.C., Webster J.P. Toxoplasma gondii infection and behaviour–location, location, location? J. Exp. Biol. 2013; 216(1): 113–9. DOI: 10.1242/jeb.074153

24. Prandovszky E., Gaskell E., Martin H., Dubey J.P., Webster J.P., McConkey G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PloS One 2011; 6(9): e23866. DOI: 10.1371/ journal.pone.0023866

25. Skallova A., Kodym P., Frynta D., Flegr J. The role of dopamine in Toxoplasma-induced behavioural alterations in mice: an ethological and ethopharmacological study. Parasitology 2006; 133(5): 525–35. DOI: 10.1017/S0031182006000886

26. Gaskell E.A., Smith J.E., Pinney J.W., Westhead D.R., McConkey G.A. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PloS One 2009; 4(3): e4801. DOI: 10.1371/journal. pone.0004801

27. Holliman R.E. Toxoplasmosis, behaviour and personality. J. Infect. 1997; 35(2): 105–10. DOI: 10.1016/S0163-4453(97)91380-3

28. Vyas A., Kim S.K., Sapolsky R.M. The effects of toxoplasma infection on rodent behavior are dependent on dose of the stimulus. Neuroscience 2007; 148(2): 342–8. DOI: 10.1016/j.neuroscience.2007.06.021

29. Berenreiterová M., Flegr J., Kuběna A. A., Němec P. The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation hypothesis. PloS One 2011; 6(12) DOI: 10.1371/journal. pone.0028925

30. Hermes G., Ajioka J.M., Kelly K. A., Mui E., Roberts F., Kasza K., Mayr T., Kirisits M.J., Wollmann R., Ferguson D., Roberts C.W., Hwang J.H., Trendler T., Kennan R.P., Suzuki Y., Reardon C., Hickey W.F., Chen L., McLeod R. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J. Neuroinflammation 2008; 5(1): 48. DOI: 10.1186/1742-2094-5-48

31. Di Cristina M., Marocco D., Galiz, R., Proietti C., Spaccapelo R., Crisanti A. Temporal and spatial distribution of Toxoplasma gondii differentiation into bradyzoites and tissue cyst formation in vivo. Infect. Immun. 2008; 76(8): 3491–501. DOI: 10.1128/IAI.00254-08

32. Guloksuz S., Van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychol. Med. 2018; 48(2): 229–44. DOI: 10.1017/S0033291717001775

33. Hamdani N., Daban-Huard C., Lajnef M., Richard J.R., Delavest M., Godin O., Le Guen E., Vederine F., Lepine J.P., Jamain S., Houenou J., Le Corvoisier P., Aoki M., Moins-Teisserenc H., Charron D., Krishnamoorthy R., Yolken R., Dickerson F., Tamouza R., Leboyer M. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. Journal Affective Disorders 2013; 148(2-3): 444-448. DOI: 10.1016/j.jad.2012.11.034

34. Del Grande C., Galli L., Schiavi E., Dell’Osso L., Bruschi F. Is Toxoplasma gondii a trigger of bipolar disorder?. Pathogens. 2017; 6(1): 3. DOI: 10.3390/pathogens6010003

35. Tedla Y., Shibre T., Ali O., Tadele G., Woldeamanuel Y., Asrat D., Aseffa A., Mihret W., Abebe M., Alem A., Medhin G., Habte A. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop. Med. J. 2011; 49(3): 211–20.

36. Miman O., Mutlu E. A., Ozcan O., Atambay M., Karlidag R., Unal S. Is there any role of Toxoplasma gondii in the etiology of obsessive–compulsive disorder? Psychiatry Res. 2010; 177(1–2): 263–5. DOI: 10.1016/j.psychres.2009.12.013

37. Brynska A., Tomaszewicz-Libudzic E., Wolanczyk T. Obsessive-compulsive disorder and acquired toxoplasmosis in two children. Europ. Child. Adolesc. Psychiatry 2001; 10(3): 200–4. DOI: 10.1007/s007870170027